Claes Wahlestedt - Publications

Affiliations: 
Neuroscience Scripps Florida, Jupiter, FL, United States 

33 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Kemper C, Benham D, Brothers S, Wahlestedt C, Volmar CH, Bennett D, Hayward M. Safety and pharmacokinetics of a highly bioavailable resveratrol preparation (JOTROL ). Aaps Open. 8: 11. PMID 35789594 DOI: 10.1186/s41120-022-00058-1  0.607
2022 Dennison JL, Volmar CH, Modarresi F, Ke D, Wang J, Gravel E, Hammond-Vignini S, Li Z, Timmons JA, Lohse I, Hayward MA, Brothers SP, Wahlestedt C. Erratum to: JOTROL, a Novel Formulation of Resveratrol, Shows Beneficial Effects in the 3xTg-AD Mouse Model. Journal of Alzheimer's Disease : Jad. PMID 35723129 DOI: 10.3233/JAD-229006  0.6
2022 Dennison JL, Volmar CH, Ke D, Wang J, Gravel E, Hammond-Vignini S, Li Z, Timmons JA, Lohse I, Hayward MA, Brothers SP, Wahlestedt C. JOTROL, a Novel Formulation of Resveratrol, Shows Beneficial Effects in the 3xTg-AD Mouse Model. Journal of Alzheimer's Disease : Jad. PMID 35034905 DOI: 10.3233/JAD-215370  0.62
2022 Khalafi S, Zhu S, Khurana R, Lohse I, Giordano S, Corso S, Al-Ali H, Brothers SP, Wahlestedt C, Schürer S, El-Rifai W. A novel strategy for combination of clofarabine and pictilisib is synergistic in gastric cancer. Translational Oncology. 15: 101260. PMID 34735897 DOI: 10.1016/j.tranon.2021.101260  0.639
2020 Kuznetsoff JN, Owens DA, Lopez A, Rodriguez DA, Chee NT, Kurtenbach S, Bilbao D, Roberts ER, Volmar CH, Wahlestedt C, Brothers SP, Harbour JW. Dual screen for efficacy and toxicity identifies HDAC inhibitor with distinctive activity spectrum for BAP1-mutant uveal melanoma. Molecular Cancer Research : McR. PMID 33077485 DOI: 10.1158/1541-7786.MCR-20-0434  0.639
2019 Lohse I, Azzam DJ, Al-Ali H, Volmar CH, Brothers SP, Ince TA, Wahlestedt C. Ovarian Cancer Treatment Stratification Using Drug Sensitivity Testing. Anticancer Research. 39: 4023-4030. PMID 31366484 DOI: 10.21873/Anticanres.13558  0.623
2019 Mustafi S, Camarena V, Qureshi R, Yoon H, Volmar CH, Huff TC, Sant DW, Zheng L, Brothers SP, Wahlestedt C, Slingerland J, Wang G. Vitamin C supplementation expands the therapeutic window of BETi for triple negative breast cancer. Ebiomedicine. PMID 30975544 DOI: 10.1016/J.Ebiom.2019.04.006  0.604
2019 Bagheri A, Habibzadeh P, Razavipour SF, Volmar CH, Chee NT, Brothers SP, Wahlestedt C, Mowla SJ, Faghihi MA. HDAC Inhibitors Induce Expression and Promote Neurite Outgrowth in Human Neural Progenitor Cells-Derived Neurons. International Journal of Molecular Sciences. 20. PMID 30841499 DOI: 10.3390/ijms20051109  0.633
2018 Copsel SN, Lightbourn CO, Barreras H, Lohse I, Wolf D, Bader CS, Manov J, Kale BJ, Shah D, Brothers SP, Perez VL, Komanduri KV, Wahlestedt C, Levy RB. BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT. Frontiers in Immunology. 9: 3104. PMID 30733722 DOI: 10.3389/fimmu.2018.03104  0.631
2018 Lohse I, Statz-Geary K, Brothers SP, Wahlestedt C. Precision medicine in the treatment stratification of AML patients: challenges and progress. Oncotarget. 9: 37790-37797. PMID 30701032 DOI: 10.18632/oncotarget.26492  0.627
2018 Janczura KJ, Volmar CH, Sartor GC, Rao SJ, Ricciardi NR, Lambert G, Brothers SP, Wahlestedt C. Inhibition of HDAC3 reverses Alzheimer's disease-related pathologies in vitro and in the 3xTg-AD mouse model. Proceedings of the National Academy of Sciences of the United States of America. PMID 30397132 DOI: 10.1073/Pnas.1805436115  0.622
2018 Lohse I, Al-Ali H, Volmar CH, D Alvarez Trotta A, Brothers SP, Capobianco AJ, Wahlestedt C. Ex vivo drug sensitivity testing as a means for drug repurposing in esophageal adenocarcinoma. Plos One. 13: e0203173. PMID 30212533 DOI: 10.1371/Journal.Pone.0203173  0.624
2018 Johnstone AL, O'Reilly JJ, Patel AJ, Guo Z, Andrade NS, Magistri M, Nathanson L, Esanov R, Miller BH, Turecki G, Brothers SP, Zeier Z, Wahlestedt C. Enhancer of Zeste 1 is an antipsychotic-sensitive epigenetic modulator of social and motivational behavior that is dysregulated in schizophrenia. Neurobiology of Disease. PMID 30099093 DOI: 10.1016/J.Nbd.2018.08.005  0.598
2017 Mustafi S, Camarena V, Volmar CH, Huff TC, Sant DW, Brothers SP, Liu ZJ, Wahlestedt C, Wang G. Vitamin C sensitizes melanoma to BET inhibitors. Cancer Research. PMID 29180474 DOI: 10.1158/0008-5472.Can-17-2040  0.651
2017 Swords RT, Azzam D, Al-Ali H, Lohse I, Volmar CH, Watts JM, Perez A, Rodriguez A, Vargas F, Elias R, Vega F, Zelent A, Brothers SP, Abbasi T, Trent J, ... Wahlestedt C, et al. Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study. Leukemia Research. 64: 34-41. PMID 29175379 DOI: 10.1016/J.Leukres.2017.11.008  0.628
2017 Volmar CH, Salah-Uddin H, Janczura KJ, Halley P, Lambert G, Wodrich A, Manoah S, Patel NH, Sartor GC, Mehta N, Miles NTH, Desse S, Dorcius D, Cameron MD, Brothers SP, Wahlestedt C, et al. M344 promotes nonamyloidogenic amyloid precursor protein processing while normalizing Alzheimer's disease genes and improving memory. Proceedings of the National Academy of Sciences of the United States of America. 114: E9135-E9144. PMID 29073110 DOI: 10.1073/Pnas.1707544114  0.633
2017 Jones C, Barrera I, Brothers S, Ring R, Wahlestedt C. Oxytocin and social functioning. Dialogues in Clinical Neuroscience. 19: 193-201. PMID 28867943  0.589
2016 Aziz AM, Brothers S, Sartor G, Holm L, Heilig M, Wahlestedt C, Thorsell A. The nociceptin/orphanin FQ receptor agonist SR-8993 as a candidate therapeutic for alcohol use disorders: validation in rat models. Psychopharmacology. PMID 27515665 DOI: 10.1016/J.Alcohol.2017.02.313  0.582
2016 Volmar CH, Wahlestedt C, Brothers SP. Orphan diseases: state of the drug discovery art. Wiener Medizinische Wochenschrift (1946). PMID 26819216 DOI: 10.1007/s10354-015-0423-0  0.613
2015 Sartor GC, Powell SK, Wiedner HJ, Wahlestedt C, Brothers SP. "Nociceptin receptor activation does not alter acquisition, expression, extinction and reinstatement of conditioned cocaine preference in mice". Brain Research. PMID 26657743 DOI: 10.1016/J.Brainres.2015.11.044  0.6
2015 Sartor GC, Powell SK, Brothers SP, Wahlestedt C. Epigenetic Readers of Lysine Acetylation Regulate Cocaine-Induced Plasticity. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 35: 15062-72. PMID 26558777 DOI: 10.1523/Jneurosci.0826-15.2015  0.611
2015 Zeier Z, Esanov R, Belle KC, Volmar CH, Johnstone AL, Halley P, DeRosa BA, Khoury N, van Blitterswijk M, Rademakers R, Albert J, Brothers SP, Wuu J, Dykxhoorn DM, Benatar M, Wahlestedt C, et al. Bromodomain inhibitors regulate the C9ORF72 locus in ALS. Experimental Neurology. 271: 241-50. PMID 26099177 DOI: 10.1016/J.Expneurol.2015.06.017  0.659
2015 Zeier Z, Esanov R, Belle KC, Volmar CH, Johnstone AL, Halley P, DeRosa BA, Khoury N, van Blitterswijk M, Rademakers R, Albert J, Brothers SP, Wuu J, Dykxhoorn DM, Benatar M, Wahlestedt C, et al. Bromodomain inhibitors regulate the C9ORF72 locus in ALS Experimental Neurology. 271: 241-250. DOI: 10.1016/j.expneurol.2015.06.017  0.596
2014 Carlsson SK, Brothers SP, Wahlestedt C. Emerging treatment strategies for glioblastoma multiforme. Embo Molecular Medicine. 6: 1359-70. PMID 25312641 DOI: 10.15252/Emmm.201302627  0.614
2014 Barrett E, Brothers S, Wahlestedt C, Beurel E. I-BET151 selectively regulates IL-6 production. Biochimica Et Biophysica Acta. 1842: 1549-55. PMID 24859008 DOI: 10.1016/J.Bbadis.2014.05.013  0.607
2014 Pastori C, Daniel M, Penas C, Volmar CH, Johnstone AL, Brothers SP, Graham RM, Allen B, Sarkaria JN, Komotar RJ, Wahlestedt C, Ayad NG. BET bromodomain proteins are required for glioblastoma cell proliferation. Epigenetics : Official Journal of the Dna Methylation Society. 9: 611-20. PMID 24496381 DOI: 10.4161/Epi.27906  0.638
2013 Andero R, Brothers SP, Jovanovic T, Chen YT, Salah-Uddin H, Cameron M, Bannister TD, Almli L, Stevens JS, Bradley B, Binder EB, Wahlestedt C, Ressler KJ. Amygdala-dependent fear is regulated by Oprl1 in mice and humans with PTSD. Science Translational Medicine. 5: 188ra73. PMID 23740899 DOI: 10.1126/Scitranslmed.3005656  0.592
2012 Mittapalli GK, Vellucci D, Yang J, Toussaint M, Brothers SP, Wahlestedt C, Roberts E. Synthesis and SAR of selective small molecule neuropeptide Y Y2 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 22: 3916-20. PMID 22607676 DOI: 10.1016/J.Bmcl.2012.04.107  0.602
2012 Modarresi F, Faghihi MA, Lopez-Toledano MA, Fatemi RP, Magistri M, Brothers SP, van der Brug MP, Wahlestedt C. Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation. Nature Biotechnology. 30: 453-9. PMID 22446693 DOI: 10.1038/Nbt.2158  0.635
2010 Brothers SP, Wahlestedt C. Therapeutic potential of neuropeptide Y (NPY) receptor ligands. Embo Molecular Medicine. 2: 429-39. PMID 20972986 DOI: 10.1002/Emmm.201000100  0.614
2010 Faghihi MA, Kocerha J, Modarresi F, Engström PG, Chalk AM, Brothers SP, Koesema E, St Laurent G, Wahlestedt C. RNAi screen indicates widespread biological function for human natural antisense transcripts. Plos One. 5. PMID 20957177 DOI: 10.1371/Journal.Pone.0013177  0.623
2010 Brothers SP, Saldanha SA, Spicer TP, Cameron M, Mercer BA, Chase P, McDonald P, Wahlestedt C, Hodder PS. Selective and brain penetrant neuropeptide y y2 receptor antagonists discovered by whole-cell high-throughput screening. Molecular Pharmacology. 77: 46-57. PMID 19837904 DOI: 10.1124/Mol.109.058677  0.622
2008 Khalil AM, Faghihi MA, Modarresi F, Brothers SP, Wahlestedt C. A novel RNA transcript with antiapoptotic function is silenced in fragile X syndrome. Plos One. 3: e1486. PMID 18213394 DOI: 10.1371/Journal.Pone.0001486  0.622
Show low-probability matches.